College aantekeningen
Summary Introduction Course - Drug Discovery & Safety (2020)
Detailed summary of the lectures.
[Meer zien]Voorbeeld 2 van de 21 pagina's
Voorbeeld 2 van de 21 pagina's
In winkelwagengesponsord bericht van onze partner
Voorbeeld van de inhoud
Summary Introduction Course – Drug Discovery and SafetyIntro
Cancer Drug Target Discovery → Computational Drug Discovery → Medicinal Chemistry → Receptor Pharmacology →
Cancer Therapeutics and Drug Safety → Image-based Computational Biology → Stem Cell Models
Aim = Discovery of novel drug targets and leads with a desired therapeutic effect and minimal adverse reactions
• Identify novel drug targets and leads through phenotypic screening for the discovery of anticancer drugs
• Establish novel safety and efficacy concepts related to the early phases of drug discovery and development
• Understand pharmacological modulation of drug targets at the molecular level
• Use computational techniques for pharmacological interaction and quantitative systems biology modelling
→ Used technologies: imaging, RNAi interference, drug screening, target discovery, cell signalling, GPCRs – kinases,
medicinal chemistry, computational biology, cheminformatics
Receptor Pharmacology
Receptor pharmacology
Drug in vivo → drug binds to target → therapeutic effect (= on-target) OR adverse effect (= off-target)
3 important questions – should be answered with yes to know whether a compound will make it to the clinic:
- Does the drug reach the site of action? - in vivo
- Does the drug bind the target? (occupancy) - in vitro assay
- Is there an on-target pharmacological effect? - in vitro assay
Drug action is all about mathematics, but you can also use Graphpad Prism
[𝐿] + [𝑅] ⇌ [𝐿𝑅] → = kon = association rate = koff = dissociation rate
Figure: association and dissociation of the ligand is a continuous process as long as the ligand is close to the target
The desired effect will only occur when the ligand & receptor are bound ([LR])
In equilibrium: 𝑘𝑜𝑛 ∗ [𝐿] ∗ [𝑅] = 𝑘𝑜𝑓𝑓 ∗ [𝐿𝑅] [L] = ligand [R] = receptor [LR] = ligand-receptor complex
→ Association determines when ligand binds to receptor | Dissociation determines how long [LR] stays together
Equilibrium dissociation constant (affinity): 𝐾𝐷 = 𝑘𝑜𝑓𝑓 ⁄𝑘𝑜𝑛 = [𝐿] ∗ [𝑅] ⁄ [𝐿𝑅] (constant = capital K)
→ More [LR] = smaller KD = higher affinity of the compound
Number of binding sites is finite → there is a max amount of binding site in the cell / in vivo
[𝑅] + [𝐿𝑅] = 𝐵𝑚𝑎𝑥
𝐵 ∗[𝐿]
[𝐿𝑅] = 𝑚𝑎𝑥 affinity & amount of ligand determine how much ligand will bind to the receptor
[𝐿]+𝐾
𝐷
→ = exponential equation: more [L] = higher [LR]
→ Plateau at some point, because [L] is in numerator & denominator
→ If [L] = KD (affinity), then you will half of your receptors occupied (Bmax / 2)
[𝐿𝑅] [𝐿]
Receptor occupancy: 𝜌𝐿 = 𝐵 = [𝐿] + 𝐾 → High [L] = high receptor occupancy
𝑚𝑎𝑥 𝐷
Measure [LR] with radioligand binding studies = label L to yield a marker (L* = radioactive, fluorescent, etc)
▪ The ideal radioligand (L*) should be: stable, tritiated, high affinity (KD ~1 nM), low non-specific binding, optimal
kinetics (temperature)
▪ Distinguish the bound ligand (L*-R) from the free ligand (L*):
- Through separation (e.g. filtration)
- Without separation (e.g. SPA)
▪ Measure [L*-R]:
- [3H], [35S]: liquid scintillation counter (use when tritiated (3H))
- [125I]: gamma counter
Saturation experiment (figure) – aim = to saturate the target with radioactive ligand
- Figure: [3H]DPCPX = antagonist | increasing [L*] results in more binding | separate specific vs. non-specific binding
- Determine non-specific binding in the presence of a high conc of non-radioactively labelled ligand → non-
radioactively labelled ligand will occupy target of interest → any binding from radioligand that you find, must be to
another target or to the membranes
- 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 = 𝑡𝑜𝑡𝑎𝑙 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 − 𝑛𝑜𝑛 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔
- Specific binding curve: Bmax = max number of binding sites | KD = affinity = radioligand- and receptor specific
- This type of experiment is often done once at the start of a project (because very high [L*] are used → $$$ & these
parameters do not change during the whole project)
- KD (affinity) should always be ~ the same for different cell membrane preparations (KD is specific for a LR pair)
- Bmax tells you sth about the sample you are using → e.g. membranes have different amounts of receptor
→ Endogenously expressed receptor always have a lower Bmax than genetically modified cell lines
→ Comparable KD values (under same conditions) | Different Bmax values (under same conditions)
, Displacement experiment (figure) = equilibrium experiment
- Figure: displacement of agonist (CCPA) & non-radioactively labelled antagonist (DPCPX)
- Increasing conc’s of displacing ligand, will result in less radioligand binding (= what you
expect when a ligand competes for the same binding site as the radioligand)
- Figure: affinities of unlabelled compounds (agonist and antagonist)
- IC50 = inhibitory conc of ligand that results in 50% binding
- Figure: DPCPX has the highest affinity for this receptor, because more ligand is needed to reach IC50
(log -8 means a higher affinity than log -6) less antagonist is needed to displace 50% of radioligand
→ The more the curve is shifted to the left, the higher the affinity of a compound
Hill-plot = linear transformation of a displacement experiment:
• Use it to get more info about the mechanism of interaction
• Hill factor (nH): says sth about type of receptor-ligand interaction
(stoichiometry) | - if it is going down | nH = (-)1.0 means there is a 1 to 1
interaction between ligand and receptor (usually the case with antagonists)
• IC50 = intercept with X-axis | depicts ligand affinity
• CCPA nH = -0.57 →
A receptor system can be depicted as a balance between active (RA) and inactive (Ri) receptors (cellular system is dynamic)
Receptor shuttles between active & inactive state in a cell → basically, you have 2 populations: active & inactive receptors
Active receptors = bound to the G-protein Inactive receptors = not bound to G-protein
In systems with genetically modified cells (high amount of receptors), there is too little G-protein → large popu of
receptors that are not bound to a G-protein & popu of receptors that has a G-protein that is endogenously available in cell
• Antagonist doesn’t discriminate between active & inactive receptor popu → binds to both equally well →
stochiometry is 1 to 1 (nH = 1.0)
• Agonist prefers to activate system → prefers to bind to active receptors
(discriminates) → stochiometry is 1 to 2 (because it sees 2 populations → nH = 0.5)
• Inverse agonist prefers to inactivate system → prefers to bind to inactive receptors
(discriminates) → stochiometry is 1 to 2 (because it sees 2 populations → nH = 0.5)
→ Antagonists & inverse agonist are often used mixed, because you need special assays to discriminate these
Challenge antagonistic radioligand with an antagonist displacer: antagonistic radioligand does not
discriminate → sees 2 groups → will displace RA and Ri equally well → no difference in affinity → 1 IC50
value (monophasic curve)
→ There are 2 populations, but because the have an identical IC50 value, you only see 1 IC50 value
Challenge antagonistic radioligand with an agonist displacer: agonist displacer will prefer RA over Ri
(discriminating) → with high enough conc’s of agonist displacer, it will also start displacing the antagonistic
radioligand from Ri → 1 affinity value for RA and 1 for Ri → 2 IC50 values (biphasic curve)
Challenge agonistic radioligand with either an antagonistic or agonist displacer: If you use an agonistic radioligand, you
only label the RA population → because you only label 1 population, you can only see 1 population
→ Always: 1 IC50 value (monophasic curve) → it is pharmacologically impossible to get a biphasic curve
𝐼𝐶50
Cheng-Prusoff equation: 𝐾𝑖 = 1+ [𝐿]⁄𝐾
𝐷
▪ Convert IC50 from the curve to a Ki value by correcting it for the concentration and affinity of L*
▪ Ki value (nM) becomes an independent value that can be compared between labs / assay protocols
→ Transform assay-dependent IC50 value to assay-independent Ki value
→ Antagonist has 1 Ki value | Agonist has 2 Ki values (n times more ligand needed to displace from Ri)
Kinetics of binding = association and dissociation of ligands to a receptor
→ How quickly a ligand associates to the receptor? How long does it stay at the receptor?
Kinetic association experiment (figure) – follow the kinetics in time (x-axis = time):
- The longer the radioligand is incubated with the receptor, the more of the radioligand will bind to the receptor
- Equilibrium plateau = where the amount of associated radioligand is equal to the amount of dissociated radioligand
→ This is not Bmax, because this is experiment is not performed under saturating concentrations
- [𝐿𝑅] = [𝐿𝑅]𝑚𝑎𝑥 ∗ (1 − 𝑒 −𝑘𝑜𝑏𝑠 ∗ 𝑡 ) = exponential equation (kobs instead of kon)
- Figure: dissociation of [3H]DPCPX by adding an excess of unlabelled ligand once the equilibrium
plateau is reached → competition for binding, but because of excess of unlabelled ligand,
[3H]DPCPX can not rebind to the receptor → dissociation of [3H]DPCPX (in time)
𝑘 ∗ 𝑡
→ [𝐿𝑅] = [𝐿𝑅]𝑡0 ∗ 𝑒 𝑜𝑓𝑓 t0 = when was experiment (with excess of unlabelled ligand) started
➔ Time-dependent & exponential
𝑘𝑜𝑏𝑠 −𝑘𝑜𝑓𝑓
- 𝑘𝑜𝑛 = [𝐿]
both experiments (association & dissociation) needed, because during association
experiment, the radioligand also dissociates → you need to correct for this dissociation & for the amount of
radioligand used in the suspension (more radioligand results in quicker association / receptor binding)
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper bfw1620. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €7,09. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 67232 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen